Funding for this research was provided by:
Received: 23 February 2020
Accepted: 28 May 2020
First Online: 13 June 2020
Compliance with ethical standards
: AKP and PS report ownership of stocks in Immunicum AB. AKP is Immunicum employee and PS Immunicum consultant. All other authors report no conflict of interest.
: The ethics review board (‘Regionala Etikprövningsnämnden i Stockholm’) approved the study 9th of December 2015 (Dnr: 2015/1619-31), as well as the Medical Product Agency (‘Läkemedelsverket’), prior to study start.
: The study was conducted in accordance with the International Conference in Harmonization-Good Clinical Practice (ICH-GCP), the Declaration of Helsinki.
: Patients were provided written and verbal information by the investigators’ about the study objectives, procedures, and possible risk associated with study participation. Prior to inclusion into the trial, all patients’ signed the informed consent form.